公开(公告)号：US10053458B2

公开(公告)日：2018-08-21

申请号：US15319151

申请日：2015-05-21

Applicant: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY

Inventor： Chang Soo Yun ,  Hyoung Rae Kim ,  Sung Yun Cho ,  Hee Jung Jung ,  Kwangho Lee ,  Chong Hak Chae ,  Chong Ock Lee ,  Chi Hoon Park ,  Pilho Kim ,  Jong Yeon Hwang ,  Jae Du Ha ,  Sun Joo Ahn

IPC: C07D471/04 ,  C07D405/14 ,  C07D401/14 ,  C07D403/12 ,  C07D401/12

CPC classification number: C07D471/04 ,  A61K31/506 ,  C07D209/04 ,  C07D239/12 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D405/14

Abstract: The present invention relates to a pyrimidine-2,4-diamine derivative or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition for prevention or treatment of cancer comprising the same as an effective ingredient. A compound according to the present invention has the good effect of inhibiting anaplastic lymphoma kinase (ALK) activity, whereby a therapeutic effect on cancer cells having an anaplastic lymphoma kinase (ALK) fusion protein such as EML4-ALK, NPM-ALK, etc. can be enhanced and it is expected that a recurrence of cancer will be effectively inhibited. As such, the compound can be effectively used in a pharmaceutical composition for prevention or treatment of cancer.